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Introduction 21
Parasitic diseases have been particularly resistant to the development of effective vaccines and safe and 22 curative therapeutic drugs. The drugs that have been put into use often suffer from one or more of the 23 problems of inefficiency, high toxicity and/or selection of drug resistant mutants. 24
Despite being one of the highest impact infectious diseases in the Americas, T. cruzi infection in humans 25
is relatively rarely treated. Initially this was because of the misconception that Chagas disease had an 26 autoimmune, rather than pathogen persistence etiology (Tarleton, 2003) but more recently the 27 substantial toxic side effects and the limited supply of benznidazole (BZN) and nifurtimox (NFX), drugs 28 that have been in use for decades, has also contributed significantly to their low rate of utilization. 29 However, the highly variable outcome of treatment regimens employing these compounds -ranging 30 from 0 to 100% depending on the study -and the difficulty of accurately assessing these outcomes, also 31 keep utilization as low as 1% of those infected ( The reason for the high variability in the efficacy of BZN and NFX is not known but has been primarily 35
attributed to the broad genetic diversity of T. cruzi isolates. Importantly, the lack of drug efficacy is 36 almost certainly not a result of selection of genetic resistance by drug use or misuse, as neither BZN nor 37 NFX have been widely or indiscriminately used and the induction of stable resistance to these drugs is 38 difficult to produce in vitro or in vivo. Further, the variable and often low contribution of humans to 39 infection of insect vectors (many infections in insects originate from feeding on non-human mammals, 40 within which T. cruzi circulates widely and at high levels (Cohen & Gurtler, 2001) ), offers very few 41 opportunities to drive and spread resistance even if it were to develop. 42
In addition to classical genetic-based drug resistance, it has become increasingly appreciated that in 43 bacterial infections, "persister" cells develop that are transiently unaffected by chemotherapy due in 44 most cases to metabolic dormancy (reviewed in (Harms, Maisonneuve, & Gerdes, 2016) ). Such 45 persisters can arise spontaneously in the presence or absence of stress signals and can reemerge after 46 the termination of environmental challenges -such as antibiotic treatment. 47
In this study, we document the occurrence of dormancy in the protozoan T. cruzi and link this 48 phenomenon to the resistance of this parasite to otherwise highly effective and cytotoxic drugs. We 49
show that both in vitro and in vivo, T. cruzi exhibits a biphasic kill curve, with the rapid death of most 50 parasites but the persistence of transiently non-replicating intracellular parasites that are resistant to 51 high level and prolonged drug exposure. 52
Results 53
The anti-T. cruzi drugs BZN and NFX are normally dosed in animals (including humans) for 30-60 days, 54 although shorter treatment times can occasionally be curative (Bustamante, Craft, Crowe, Ketchie, & 55 Tarleton, 2014; Viotti et al., 2011) . This general requirement for a long treatment course and the 56 variability in outcome is inconsistent with the documented rapid trypanocidal activity of BNZ for T. cruzi 57 in vitro (Moraes et al., 2014) , although to our knowledge, kill rates had not previously been determined 58 in vivo. To directly assess the activity of BNZ in vivo, we first established a localized infection of T. cruzi 59 in the footpads of mice and then used a transgenic luciferase reporter to monitor the loss of parasites 60 subsequent to a single oral dose of BNZ. We first determined that T. cruzi trypomastigotes delivered in 61 the footpad or skin, primarily infect host cells at the infection site (rather than distributing systemically) 62 and expand as amastigotes within these host cells during the subsequent ~96 hrs (Padilla, et al., in 63 preparation). Administration of a single oral dose of BZN reduced intracellular amastigotes at the initial 64 infection site by ~90% within 48 hrs ( Fig 1A-C) . A similarly rapid reduction in parasite load occurs in mice 65
with established systemic infections within a few days after the initiation of oral BZN treatment ( Fig 1D-66 F). In this later experiment we used multiple T. cruzi isolates, including two (colombiana and ARC-0704) 67 previously determined to be relatively more resistant to BZN in vivo (Bustamante et al., 2014) . The rate 68 of parasite clearance, approaching the limit of detection by imaging, was similar for all three strains and 69 in the case of the colombiana infection, the 5 days of treatment resulted in a >3 log10 reduction in 70 systemic parasite load. Thus, consistent with previous in vitro assessments, BZN rapidly and highly 71 effectively kills both "resistant" and "susceptible" T. cruzi strains in vivo. 72
While these experiments demonstrate that BZN treatment rapidly reduces T. cruzi numbers by 10-to 73 1000-fold over just a few days, we know from previous studies that such short-term treatments, and 74 indeed treatments as long as 60 days, often fail to completely clear T. cruzi infection (Bustamante et al., 75 2014) . This disconnect implicates a mechanism by which T. cruzi can resist highly effective trypanocidal 76 drugs for an extended period of time. To investigate whether dormant/non-replicating forms of T. cruzi 77 might be present in infected hosts and possibly contributing to this requirement for long treatment 78 regimens, we used in situ labeling with nucleotide analog 5-ethynyl-2'-deoxyuridine (EdU) to determine 79 the replication status of parasites within tissues of infected mice. We first established the in vivo EdU 80 labeling protocol in acutely infected mice with high tissue parasite load, finding that the vast majority of 81 amastigotes incorporated EdU during a 24 hr period after EdU injection (Sup Fig 1) . We then applied 82 this protocol to mice with established chronic T. cruzi infections and again found that most intracellular 83 amastigotes incorporated EdU over the 24-72 hrs of exposure. However a small fraction of intracellular 84 amastigotes failed to show evidence of replication over the 72 hours after EdU injection ( Figure 2 and 85 Sup Fig. 2 ). Interestingly, these apparently non-replicating amastigotes were within host cells in which 86 the other amastigotes were clearly replicating, suggesting that there is a heterogeneity of amastigotes in 87 infected cells. Since the low parasite load in chronically infected mice makes it highly unlikely that a 88 single host cell is infected by more than one trypomastigote, this heterogeneity in replication appears to 89 establish within host cells from a single infecting parasite. 90
To examine in greater detail the replication pattern of T. cruzi in host cells, we moved to in vitro systems 91
wherein large numbers of infected cells can be readily monitored longitudinally during infection and the 92 continuous exposure to EdU can be assured. As in the in vivo infection, a small fraction of amastigotes 93 in host cells in vitro consistently failed to take up EdU, even when exposed for up to 72 hrs of the ~96 94 hrs intracellular replication phase ( Figure 3 ). One possible reason for the failure to replicate is that some 95 amastigotes might die within host cells (perhaps as a result of lethal damage to DNA, defective 96 cytokinesis, or unequal dispersal of chromosomes/organelles during prior replication, among other 97 possible reasons). However monitoring for apoptosis of amastigotes in host cells revealed this process 98 to be extremely rare (Sup Fig 3) . 99
Incorporation of EdU into DNA can impact DNA replication and thus cell division (Zhao et al., 2013) . To 100 rule out a role for EdU itself in inhibition of parasite replication, we used the cell division tracker dyes 101 carboxyfluorescein succinimidyl ester (CSFE) and CellTrace Violet as a second method to monitor 102 parasite replication in host cells. Both dyes couple to cellular components and are equally distributed to 103 daughter cells during cytokinesis and with vigorous replication, the dyes are eventually diluted beyond 104 the point of detection. T. cruzi trypomastigotes uniformly stain with either dye and upon infection of 105 host cells, replicating amastigotes dilute the dye, while a fraction of amastigotes remain dye positive, 106
indicating again the limited replication of a subset of amastigotes ( Fig 4A and B ). Amastigotes remaining 107 dye positive after 72-96 hrs were also EdU-negative ( Fig 4C) . 108
By continuing to monitor infected host cells over time, we observed that amastigotes that had failed to 109 incorporate EdU during the final ~72 hrs in host cells were fully competent to convert to 110 trypomastigotes and to exit host cells, along with the previously replicating (EdU+) trypomastigotes 111 ( Figure 4D , E). The use of the CellTrace Violet to mark parasites that had undergone a limited number or 112 no divisions during the infection cycle in host cells allowed us to further characterize and ultimately 113 isolate this minority population of trypomastigotes from infected cell cultures ( Figure 4F and G), and to 114 assess their ability to establish a second round of infection/replication in new host cells. Not only could 115 trypomastigotes from minimally replicating amastigotes infect new host cells, re-convert to amastigotes 116 ( Fig 5A) , and begin a new round of replication, but progeny of this replication can also stop dividing soon 117 after invasion and retain dye for >6 days while other progeny of this dormant amastigote divided 118 extensively ( Fig 5B) . Thus, a small proportion of T. cruzi amastigotes halt replication within 24 hrs after 119 host cell entry but can convert to trypomastigotes that are infection-competent and able to repeat the 120 processes of replication and arrested replication in new host cells ( Fig 5C) . 121
The detection of a small subpopulation of T. cruzi undergoing minimal replication through 2 rounds of 122 host cell invasion suggests that the cessation of replication can at a minimum happen early after host 123 cell invasion, but did not preclude a more dynamic pattern of transitioning between replication and 124 dormancy during the infection cycle in host cells. In order to better understand the flexibility and 125 heterogeneity of replication within host cells, we monitored the early replication of T. cruzi in host cells 126 by time-lapse video, using violet dye dilution to help mark those parasites undergoing minimal cell 127 division within the same cell where other parasites are actively dividing (Sup Video 1 and 2).These 128
videos also indicate other characteristics of non-dividing amastigotes that were apparent in other still 129
images, e.g. that non-dividing amastigotes are similar in size to recently divided amastigotes and are 130
generally Tdtomato-dim, expressing low levels of the Tdtomato fluorescent protein relative to rapidly 131 dividing amastigotes. 132
These results show conclusively that within host cells infected with T. cruzi, a subset of amastigotes 133 cease replication while others continue rapid division, eventually filling the host cell with amastigotes. 134
The obvious question remaining is 'Does this cessation of replication play a critical role in the failure of 135 drugs to effectively clear T. cruzi infection?' More specifically, are these replication-arrested parasites 136 resistant to drug treatment. To directly address these questions, we infected mice with Tdtomato-137 expressing and CellTrace Violet-stained trypomastigotes and confirmed 2 days post-infection the 138 presence of parasites in adipose tissue expressing both of these markers ( Fig 6A and B) . As expected 139 based on previous experiments, over the span of the 2 day infection, several strongly violet-positive 140 parasites are obvious in cells along with a larger number of parasites in which the violet dye was faint or 141 not detectable, indicating both slow or non-replicating and actively replicating progeny of the infecting 142 trypomastigotes. On days 2 and 3, similarly infected mice were treated with BZN or left untreated and 143 on day 4, examined for the presence of parasites. Remarkably, in the BZN-treated mice, the only 144 parasites detected were brightly violet and present at 1 and occasionally 2 per infected cell ( Fig 6B and  145 Sup Fig 5A) . No violet-negative parasites were detected in the BZN-treated mice while a much larger 146 number of violet negative and less abundant violet-positive parasites were observed in the non-treated 147 mice. A resumption of parasite replication was evident in treated mice 9 days after the last of the 2 BNZ 148 treatment doses, demonstrating that dormant, and therefore drug resistant amastigotes could also 149 resume division in vivo. To further address the drug resistance and recovery potential of dormant 150 amastigotes in vivo, we repeated these experiments in interferon-gamma deficient mice, which lack the 151 ability to develop immune control of T. cruzi infection. Non-replicating amastigotes developing in these 152 mice survive a minimum of 20 days of BZN treatment (Sup Fig 5A) and again resume replication upon 153 cessation of BZN treatment ( Fig 6C) and eventually spread extensively in these animals (Sup Fig 5B, C) . 154
Tracking very low numbers of persisting parasites in vivo in drug-treated, infected animals is quite 155 difficult, so we returned to in vitro systems to examine the resistance of T. cruzi to drug treatment over 156 longer time periods and the association of drug resistance to dormancy. Here we infected host cells 24 157 hrs previously with Tdtomato-expressing and CellTrace Violet-labeled parasites and then added BZN at 158
10X the IC50 for up to 30 days of culture before washing out the drug. Parasite recovery following drug 159 treatment/washout was monitored globally by whole-well fluorescence detection of the Tdtomato 160
reporter, and at the individual cell level by microscopy (Fig 7) . In the absence of treatment, parasite 161 numbers peak near the time of the completion of the first round of intracellular replication (~ day 4 162 after infection). In all cases, even following 30 days of high dose BZN treatment, parasites can rebound 163 and begin replication after BZN is removed. This rebound can often be observed in the whole well 164 Tdtomato fluorescence readings ( Fig 7A) , and in all cases, low numbers of parasites with a range of 165 violet dye retention are evident in cultures during drug treatment ( Fig 7B) , as well as resumption of low 166 level to vigorous replication after drug washout ( Fig 7C) . The resistance of T. cruzi to drug treatment 167 due to amastigote dormancy was not restricted only to BNZ, as members of a class of newly developed 168 oxaborale compounds currently under preclinical development also failed to overcome dormancy-169 dependent resistance in vitro (Sup Fig 6) . Further, T. cruzi lines rebounding after 30 days of in vitro 170 exposure to BZN had not developed stable resistance to the compound as the IC50 of BZN on this 171 population remained unchanged from that of the pre-exposed population (Sup Fig 7) . demonstrating these compounds to be clearly inferior to BNZ and NFX. 190 This study initially sought to determine why compounds like BZN that can, and often do, provide sterile 191 cure in T. cruzi infection, also frequently fail. This and previous studies have largely ruled out several 192 mechanisms as primary reasons for the variable efficacy of BZN. Although there is parasite strain 193 variation with respect to BZN susceptibility in vivo, this variation does not appear to be due to direct 194 resistance to the trypanocidal activity of BZN ( Figure 1 ). Parasite lines obtained from failed drug 195 treatments are no more resistant to BZN than the pre-treatment parasites (Sup Fig 7) , and although BZN 196 resistance can be induced by drug selection in vitro, such partially resistant lines are crippled with 197 respect to initiating and maintaining an infection (Mejia et al., 2012) . Thus resistance to BZN treatment 198 is relative, not complete, is not easily selectable, and is not associated with any specific genetic lineage 199 of T. cruzi nor with host genetics. 200
The results of the current study firmly connect drug treatment failure in T. cruzi infection to the 201 presence of a previously unrecognized player in this parasite's life cycle, the transiently dormant 202 amastigote. We denote these stages as dormant based primarily on their failure to replicate over an 203 extended period of time and their resistance to trypanocidal compounds over >30 days of exposure. 204
These dormant amastigotes appear at a consistently detectable frequency and are present in many 205 infected host cells in vitro and in vivo. Dormancy occurs spontaneously and is often observed soon after 206 host cell infection -as shown by the ability of parasites to retain cell division monitoring dyes through 207 several rounds of host cell invasion and expansion. However dormancy may also occur at other points 208 throughout the 4-5 day replication cycle within host cells, as suggested by the presence of multiple EdU-209 negative amastigotes in heavily infected cells and supported by time lapse imaging of infected cells. 210
Importantly, these dormant parasites are not permanently arrested, as they resume replication days to 211 weeks after entering dormancy (Fig 7) . These dormant amastigotes also readily respond to the cues that 212 drive conversion to trypomastigote forms within host cells, a process that appears to occur only when 213 the host cell is nearly bursting with amastigotes. Candidates for the inducer of stage conversion would 214 include depleted host cytoplasmic components or byproducts of parasite metabolism that could 215 accumulate inside the host cell. Thus the dormant amastigotes have two potential fates besides 216
continued dormancy: to re-initiate replication like conventional amastigotes -likely to occur when there 217 are none or a limited number of other amastigotes in the cell -or to convert to trypomastigotes in 218 concert with the actively replicating amastigotes undergoing that process within the same cells. An 219 extremely rare outcome for amastigotes in host cells is death, as determined by the paucity of degrading 220 amastigotes detected in host cells (Sup Fig 3) . 221
Dormancy is well-studied in bacteria and plays a critical role in their adaptation to changing 222 environments. quiescent and as a result were not detected by the immune system. Such persisters could then "wake-255
up" and begin replication weeks or months later. But those reawakened parasites would likely remain 256 low in numbers as they would have to contend with the now established anti-T. cruzi immune response 257 in order to expand and have an increased chance of being transmitted. Thus the selective pressure for 258 development or retention of a dormancy pathway for this purpose alone seems very low. 259
Alternatively, dormancy might be a consequence of the biology of T. cruzi, rather than an evolutionarily 260 selected process for low-level persistence. T. cruzi very rarely undergoes sexual recombination but 261 instead depends heavily on gene amplification and recombination, as well as horizontal gene transfer, 262
for generating genetic diversity. The resorting of genetic material likely takes place in amastigotes, one 263 of the 2 replicating stages in the T. cruzi life cycle. Parasites that enter dormancy soon after host cell 264 invasion could be pre-recombination, "stem-like" cells that would be useful should the genetic 265 recombination events in the replicating parasites go awry. Alternatively, parasites might enter 266 dormancy in order to sort out the result of recombination events before proceeding with additional 267 rounds of replication. 268
Whether stochastic or programmed, the mechanisms for entering and exiting the dormant state by T. 269
cruzi is a complete black box. Hints about the process may come from understanding the events 270 involved in transitioning from replicating stages to non-replicating stages in T. cruzi (e.g. epimastigotes 271
to infective metacyclic trypomastigote and amastigote to blood stage trypomastigote) or in the related 272
African trypanosome Trypanosoma brucei, which although lacking an intracellular stage, makes several 273 well-characterized transitions from replicating to non-replicating forms. 274
The biggest practical message from the current study is that dormancy in the mammalian infection cycle 275 of T. cruzi is key to the failure of current drug treatments for T. cruzi infection. While other factors, 276
including the differential tissue tropism of parasite strains and tissue distribution of potential drugs, 277
certainly also impact treatment outcomes, only dormancy has been definitively linked. Given this new 278
understanding of dormancy and its impact on drug treatment, simply identifying more compounds that 279 effectively kill metabolically active parasites is not likely on its own to be the solution to achieving more 280 dependable cure in T. cruzi infection. Tdtomato-expressing parasites (5:1 ratio parasites:host cells) and incubated for 6 days at 37C in 5% CO2. 378
Free trypomastigotes released to the supernatant were harvested and imaged using an ImageStream 379
Mark II (MilliporeSigma, MA). CellTrace Violet Td-tomato positive parasites from those supernatants 380
were sorted using a MoFlo XDP (Beckman Coulter, FL) and placed in fresh Vero cell cultures that were 381 periodically monitored and imaged using a Cytation 5 imager (BioTek). 382
In vitro drug treatment and washout assays. Gamma-irradiated Vero cells at 25,000/well were infected 383 with 150,000 colombiana strain Tdtomato-luciferase trypomastigotes in each well of a 96 well plate 384
(Greiner Bio-one) for 24 hrs. After removing non-infecting trypomastigotes, 10 uM BZN (approx. 10X 385 IC50) in complete RPMI media was added. The 6 replicate wells for each condition were read using 386
BioTek Synergy Hybrid reader and images were taken by BioTek Cytation 5. At the indicated times post-387 treatment, BZN was removed, cultures washed and fresh medium without BZN added. Spent medium 388 was removed and fresh medium with or without BZN were added weekly. Additional (15,000/well) Vero 389 cells were added biweekly. The relative in vitro resistance to drug treatment by T. cruzi lines was 390 determined as previously described (Canavaci et al., 2010) , and IC50 was calculated using the GraphPad 391 PRISM 5.0 software. 392
Statistical analysis. The Mann-Whitney U tests and one-way variance analysis (ANOVA) of the GraphPad 393
Prism version 5.0 software were used. Values are expressed as means ± standard error of mean of at 394 least three separate experiments. P values equal to or minor that 0.05 were considered significant. 395
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